Trial for gout drug meets primary endpoint, raises safety Febuxostat, a gout drug that has been in use for nearly a decade, was found to significantly increase the risk of death, even though it did not raise the risk of the trial's primary endpoint, a combined rate of fatal and nonfatal adverse cardiovascular events, according to new research. http://ift.tt/eA8V8J
Monday, 12 March 2018
Tags
# Latest Science News -- ScienceDaily
![Author Image]()
About Unknown
Templatesyard is a blogger resources site is a provider of high quality blogger template with premium looking layout and robust design. The main mission of templatesyard is to provide the best quality blogger templates which are professionally designed and perfectlly seo optimized to deliver best result for your blog.
Subscribe to:
Post Comments (Atom)
Hello, my name is Jack Sparrow. I'm a 50 year old self-employed Pirate from the Caribbean.
No comments:
Post a Comment